- $5.48bn
- $4.46bn
- $4.04m
CG Oncology Q2 net loss widens on higher R&D costs
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple
U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
U.S. STOCKS ON THE MOVE -Health insurers, Arista, Savara
U.S. STOCKS ON THE MOVE -Virgin Galactic, Humana, Broadcom
CG Oncology rises after brokerage lifts PT ahead of pivotal bladder cancer data
Brief: Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc
Brief: CG Oncology Inc - Announced Topline Data From Bond-003 Cohort P And First Results From Core-008 Cohort A
U.S. RESEARCH ROUNDUP-Applied Materials Inc, Blackstone Mortgage, Brookdale Senior Living
Brief: Robert Lapetina Resigned As CG Oncology's Interim Financial Officer On Nov 10 - SEC Filing
Brief: Cg Oncology Inc Delaware Superior Court Jury Issues Unanimous Verdict That Co Owes No Future Royalties Or Other Payments To Ani Pharmaceuticals
CG Oncology jumps after late-stage bladder cancer therapy data
Brief: CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec
U.S. RESEARCH ROUNDUP- 3M, Citigroup, Nvidia
Brief: CG Oncology Inc Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing
Brief: CG Oncology Reports 2024 Year End Financial Results And Provides Business Updates
ANI Pharma rises after J.P.Morgan initiates coverage with 'overweight' rating
CG Oncology dips after pricing stock offering